Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)

NCT01276405 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01276405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01276405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Terminated
Start date
March 31, 2010
Completion date
October 31, 2015
Enrollment
123 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer